Safety, plainly explained.

The most common reaction in the first few weeks is a mild itch or tingle in the mouth, lips, or under the tongue right after brushing. It’s expected, usually fades within twenty minutes, and almost always resolves over the first month as your immune system adjusts to the calibrated allergen exposure.

A few people notice a small change in saliva flow or a brief mint-mild aftertaste beyond what they’d expect from regular toothpaste. Those reactions also taper with continued use. None of this is unusual for mucosal immunotherapy.

The 2025 Phase 1 toothpaste-vehicle OMIT trial (OMEGA / INT301, sponsored by Intrommune Therapeutics and published in Annals of Allergy, Asthma & Immunology; authored by Berger et al., not Easily’s team) reported zero participants discontinued due to side effects. Caveat: the OMEGA cohort was peanut allergy, not airborne — we cite it for vehicle and route safety, not for an Easily-product claim. The earlier Reisacher 2016 head-to-head trial in airborne allergic rhinitis reported no lower-airway or cardiovascular reactions in either arm, and no gastrointestinal events in the OMIT group. The published evidence is small but consistent.

Severe systemic reactions to mucosal immunotherapy are rare. They are not zero. Stop using the product and seek emergency care immediately for any sign of throat tightness, difficulty breathing, hives spreading beyond the face or mouth, or lightheadedness or dizziness. These are not normal at any stage of treatment.

Call 911 for active throat tightness, breathing difficulty, fainting, or rapidly spreading hives. Message your care team for oral swelling that lasts more than thirty minutes, persistent itch beyond the first month, any new wheeze, or a rash that spreads. We’d rather pause one dose than miss a signal.

The eligibility quiz screens for the conditions below. If any apply, we don’t ship — we’ll suggest talking with your doctor instead.

• Pregnancy or breastfeeding. Immunotherapy isn’t initiated during pregnancy or while breastfeeding; the immunological literature on initiation during these states is too thin to start safely.
• Prior anaphylaxis to any allergy immunotherapy. A previous severe reaction to shots, drops, or oral immunotherapy means OMIT isn’t the safest choice for your situation.
• Severe or uncontrolled asthma. Specifically, asthma that requires a rescue inhaler more than once a week. Get the asthma controlled first; revisit immunotherapy after.
• Current beta-blocker therapy. Beta-blockers blunt the body’s response to epinephrine, the first-line treatment for systemic allergic reactions. That makes any immunotherapy meaningfully riskier.
• Active immunosuppressant therapy. Immunotherapy works by training your immune system; an immunosuppressed system can’t reliably learn the tolerance pattern, and the safety profile is different.
• Under eighteen. Pediatric (ages 5+) is a fast-follow track planned for after platform launch, with a separate medical advisor and an updated exclusion list. We don’t ship to under-18 patients in v1.

If your situation changes after you start — new pregnancy, a new asthma diagnosis, a new prescription — message your care team. We pause prescriptions before they become unsafe; we don’t ship through life changes.

Every patient takes the eligibility quiz. The quiz screens for the six exclusions above, the age cutoff, and a handful of medical-history questions that flag situations a US-licensed provider needs to look at directly. Anything flagged routes the intake to provider review before a prescription is written.

A US-licensed allergy specialist reviews every treatment plan before the pharmacy compounds anything. After you start, async messaging with your care team is included — routine questions are answered within one business day, anything safety-flagged gets same-day attention. The quiz is the first gate; the provider review is the second; ongoing messaging is the third. No part of that chain is automated past a clinical decision.